Enjoy complimentary customisation on priority with our Enterprise License!
Chagas disease is also known as American trypanosomiasis as it is caused by Tryopanosoma cruzi. It is a vector-borne disease and has two phases, i.e., acute phase and the chronic phase. A patient in chronic phase experiences cardiac and intestinal complications. Patients suffering from this condition experience symptoms such as diarrhea, enlarged lymph glands, and heart inflammation and meningoencephalitis.
Many organizations such as the World Health Organization and Drugs for Neglected Diseases initiatives (DNDi) are developing a low-cost drug for the treatment of Chagas disease by collaborating with various pharmaceutical companies. Technavio’s market research analysts have predicted that with the introduction of such medicines as one of the most promising approaches to treat Chagas disease, the Chagas disease treatment industry size will grow in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the discovery development stage. For instance, sponsors such as Astellas Pharma developed Novel compound and Savant HWP developed 18-MC, which are under discovery development stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under phase I, phase II, and phase III development stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are in the pre-clinical stage.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of Chagas disease. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
According to Chagas disease treatment market insights, the oral route of administration (ROA) involves the administration of drug substances through a mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.
According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for a Chagas disease are being developed as small molecules. Small molecules are chemically manufactured active substances that are able to enter the cells easily because of their low molecular weight.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.